Cover Image
市場調查報告書

疤痕增長症 : 開發平台分析

Keloids - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 257827
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
疤痕增長症 : 開發平台分析 Keloids - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 46 Pages
簡介

所謂疤痕增長症是指皮膚受傷回復後疤痕組織過度增殖這樣的疾病。主要症狀有皮膚變為肉色(紅·粉紅等),大量產生疙瘩,皮膚僵硬化,摩擦服裝類等時候會感到發癢,容易受傷等。主要的風險要素有年齡和家族病史等。主要的治療方法有皮質類固醇和放射治療,外科摘除手術,矽凝膠,膏藥等。

本報告提供全球各國治療疤痕增長症用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

疤痕增長症概要

治療藥的開發

  • 疤痕增長症開發中產品:概要
  • 疤痕增長症開發中產品:比較分析

各企業開發中的疤痕增長症治療藥

大學/研究機關研究中的疤痕增長症治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

疤痕增長症治療藥:開發中的產品一覽(各企業)

疤痕增長症治療藥:研究中的產品一覽(大學/研究機關別)

疤痕增長症治療藥的開發企業

  • RXi Pharmaceuticals Corporation
  • Vida Therapeutics Inc.

疤痕增長症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • CIGB-128
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • CM-101
  • koebnerisin
  • psoriasin
  • RXI-109
  • V-2248
  • VTI-3000 Series

疤痕增長症治療藥:開發中產品的最新趨勢

疤痕增長症治療藥:暫停開發的產品

疤痕增長症治療藥:中止開發的產品

疤痕增長症相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9421IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H1 2017, provides an overview of the Keloids (Dermatology) pipeline landscape.

Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keloids - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Keloids (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Keloids (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Keloids (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keloids (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keloids (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keloids (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keloids (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Keloids - Overview
    • Keloids - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Keloids - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Keloids - Companies Involved in Therapeutics Development
    • FirstString Research Inc
    • RXi Pharmaceuticals Corp
    • Topadur Pharma AG
    • Tumorend LLC
    • viDA Therapeutics Inc
    • Yuhan Corp
  • Keloids - Drug Profiles
    • CM-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Granexin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • koebnerisin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • psoriasin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXI-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOPN-44 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • V-2248 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTI-3000 Series - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YH-siRNA1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Keloids - Dormant Projects
  • Keloids - Discontinued Products
  • Keloids - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
      • Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
      • Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
      • Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
      • Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
      • Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109
      • Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Keloids, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Keloids - Pipeline by FirstString Research Inc, H1 2017
  • Keloids - Pipeline by RXi Pharmaceuticals Corp, H1 2017
  • Keloids - Pipeline by Topadur Pharma AG, H1 2017
  • Keloids - Pipeline by Tumorend LLC, H1 2017
  • Keloids - Pipeline by viDA Therapeutics Inc, H1 2017
  • Keloids - Pipeline by Yuhan Corp, H1 2017
  • Keloids - Dormant Projects, H1 2017
  • Keloids - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Keloids, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top